Ziying Lin1, Lixia Huang2, Shao Li Li2, Jincui Gu2, Xiaoxian Cui3, Yanbin Zhou4. 1. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. lzying@mail2.sysu.edu.cn. 2. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 3. Department of Respiratory Medicine, The 8th Affiliated Hospital of Sun Yat-sen University, Shenzhen, China. 4. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. zhouyb@mail.sysu.edu.cn.
Abstract
BACKGROUND: Recent evidences had shown that loss in phosphatase and tensin homolog deleted on chromosome 10 (PTEN) was associated with immunotherapy resistance, which may be attributed to the non-T-cell-inflamed tumor microenvironment. The impact of PTEN loss on tumor microenvironment, especially regarding T cell infiltration across tumor types is not well understood. METHODS: Utilizing The Cancer Genome Atlas (TCGA) and publicly available dataset of immunotherapy, we explored the correlation of PTEN expressing level or genomic loss with tumor immune microenvironment and response to immunotherapy. We further investigated the involvement of PI3K-AKT-mTOR pathway activation, which is known to be the subsequent effect of PTEN loss, in the immune microenvironment modulation. RESULTS: We reveal that PTEN mRNA expression is significantly positively correlated with CD4/CD8A gene expression and T cells infiltration especially T helpers cells, central memory T cell and effector memory T cells in multiples tumor types. Genomic loss of PTEN is associated with reduced CD8+ T cells, type 1 T helper cells, and increased type 2 T helper cells, immunosuppressed genes (e.g. VEGFA) expression. Furthermore, T cell exclusive phenotype is also observed in tumor with PI3K pathway activation or genomic gain in PIK3CA or PIK3CB. PTEN loss and PI3K pathway activation correlate with immunosuppressive microenvironment, especially in terms of T cell exclusion. PTEN loss predict poor therapeutic response and worse survival outcome in patients receiving immunotherapy. CONCLUSION: These data brings insight into the role of PTEN loss in T cell exclusion and immunotherapy resistance, and inspires further research on immune modulating strategy to augment immunotherapy.
BACKGROUND: Recent evidences had shown that loss in phosphatase and tensin homolog deleted on chromosome 10 (PTEN) was associated with immunotherapy resistance, which may be attributed to the non-T-cell-inflamed tumor microenvironment. The impact of PTEN loss on tumor microenvironment, especially regarding T cell infiltration across tumor types is not well understood. METHODS: Utilizing The Cancer Genome Atlas (TCGA) and publicly available dataset of immunotherapy, we explored the correlation of PTEN expressing level or genomic loss with tumor immune microenvironment and response to immunotherapy. We further investigated the involvement of PI3K-AKT-mTOR pathway activation, which is known to be the subsequent effect of PTEN loss, in the immune microenvironment modulation. RESULTS: We reveal that PTEN mRNA expression is significantly positively correlated with CD4/CD8A gene expression and T cells infiltration especially T helpers cells, central memory T cell and effector memory T cells in multiples tumor types. Genomic loss of PTEN is associated with reduced CD8+ T cells, type 1 T helper cells, and increased type 2 T helper cells, immunosuppressed genes (e.g. VEGFA) expression. Furthermore, T cell exclusive phenotype is also observed in tumor with PI3K pathway activation or genomic gain in PIK3CA or PIK3CB. PTEN loss and PI3K pathway activation correlate with immunosuppressive microenvironment, especially in terms of T cell exclusion. PTEN loss predict poor therapeutic response and worse survival outcome in patients receiving immunotherapy. CONCLUSION: These data brings insight into the role of PTEN loss in T cell exclusion and immunotherapy resistance, and inspires further research on immune modulating strategy to augment immunotherapy.
Entities:
Keywords:
Immunotherapy; PI3K signaling; PTEN; T cells; Tumor immune microenvironment
Authors: Isabel Garcia-Cao; Min Sup Song; Robin M Hobbs; Gaelle Laurent; Carlotta Giorgi; Vincent C J de Boer; Dimitrios Anastasiou; Keisuke Ito; Atsuo T Sasaki; Lucia Rameh; Arkaitz Carracedo; Matthew G Vander Heiden; Lewis C Cantley; Paolo Pinton; Marcia C Haigis; Pier Paolo Pandolfi Journal: Cell Date: 2012-03-06 Impact factor: 41.582
Authors: Junfei Zhao; Andrew X Chen; Robyn D Gartrell; Andrew M Silverman; Luis Aparicio; Tim Chu; Darius Bordbar; David Shan; Jorge Samanamud; Aayushi Mahajan; Ioan Filip; Rose Orenbuch; Morgan Goetz; Jonathan T Yamaguchi; Michael Cloney; Craig Horbinski; Rimas V Lukas; Jeffrey Raizer; Ali I Rae; Jinzhou Yuan; Peter Canoll; Jeffrey N Bruce; Yvonne M Saenger; Peter Sims; Fabio M Iwamoto; Adam M Sonabend; Raul Rabadan Journal: Nat Med Date: 2019-02-11 Impact factor: 53.440
Authors: Romualdo Barroso-Sousa; Tanya E Keenan; Eliezer M Van Allen; Sara M Tolaney; Sonia Pernas; Pedro Exman; Esha Jain; Ana C Garrido-Castro; Melissa Hughes; Brittany Bychkovsky; Renato Umeton; Janet L Files; Neal I Lindeman; Laura E MacConaill; F Stephen Hodi; Ian E Krop; Deborah Dillon; Eric P Winer; Nikhil Wagle; Nancy U Lin; Elizabeth A Mittendorf Journal: Clin Cancer Res Date: 2020-02-04 Impact factor: 12.531
Authors: J O Lee; H Yang; M M Georgescu; A Di Cristofano; T Maehama; Y Shi; J E Dixon; P Pandolfi; N P Pavletich Journal: Cell Date: 1999-10-29 Impact factor: 41.582
Authors: Suzanne George; Diana Miao; George D Demetri; Dennis Adeegbe; Scott J Rodig; Sachet Shukla; Mikel Lipschitz; Ali Amin-Mansour; Chandrajit P Raut; Scott L Carter; Peter Hammerman; Gordon J Freeman; Catherine J Wu; Patrick A Ott; Kwok-Kin Wong; Eliezer M Van Allen Journal: Immunity Date: 2017-02-21 Impact factor: 31.745
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Weiyi Peng; Jie Qing Chen; Chengwen Liu; Shruti Malu; Caitlin Creasy; Michael T Tetzlaff; Chunyu Xu; Jodi A McKenzie; Chunlei Zhang; Xiaoxuan Liang; Leila J Williams; Wanleng Deng; Guo Chen; Rina Mbofung; Alexander J Lazar; Carlos A Torres-Cabala; Zachary A Cooper; Pei-Ling Chen; Trang N Tieu; Stefani Spranger; Xiaoxing Yu; Chantale Bernatchez; Marie-Andree Forget; Cara Haymaker; Rodabe Amaria; Jennifer L McQuade; Isabella C Glitza; Tina Cascone; Haiyan S Li; Lawrence N Kwong; Timothy P Heffernan; Jianhua Hu; Roland L Bassett; Marcus W Bosenberg; Scott E Woodman; Willem W Overwijk; Gregory Lizée; Jason Roszik; Thomas F Gajewski; Jennifer A Wargo; Jeffrey E Gershenwald; Laszlo Radvanyi; Michael A Davies; Patrick Hwu Journal: Cancer Discov Date: 2015-12-08 Impact factor: 39.397
Authors: Adam A Kraya; Kara N Maxwell; Monika A Eiva; Bradley Wubbenhorst; John Pluta; Michael Feldman; Anupma Nayak; Daniel J Powell; Susan M Domchek; Robert H Vonderheide; Katherine L Nathanson Journal: JCO Precis Oncol Date: 2022-02